- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02968979
Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer. (CacheMire)
Cross-sectional, Multicentric, Non-interventional Study to Assess the Frequency and the Management of Cachexia and Associated Symptoms in Patients With Non-small Cell Lung Cancer.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a cross-sectional, non-interventional, European (France and Belgium), multicentric prevalence study, conducted on a representative population of 500 patients with NSCLC, to assess the frequency and the management of cachexia and associated symptoms.
The study will be conducted in accordance with the professional code of ethics and the good epidemiological practices guidelines developed by the ADELF (the Association of French-Speaking Epidemiologists) and in accordance with the STROBE recommendations for the drafting of reports and publications related to the study.
The information will be collected during a single visit to the oncologist/lung specialist as part of the usual patient management of his/her lung cancer. The physician will explain the purpose of the study to the patient with an information form specific to the study and will inform him/her of the option to refuse or withdraw from participation. The patient information form in France or a specific consent form in Belgium will be signed by the patient and a copy will be given to him/her (the original will be kept by the physician).
This study does not require any additional specific data. Data will come from the medical file and from the routine disease management. Furthermore, the following self-completion questionnaires will be proposed to patients: Visual analogue scale for dietary intake (dietary intake VAS), assessment of the concerns associated with the anorexia/cachexia (Anorexia-Cachexia module of the Functional Assessment of Anorexia/Cachexia Therapy [FAACT] questionnaire), quality of life (EORTC QLQ-C30), and assessment of physical activity (IPAQ, International Physical Activity Questionnaire). Abdominal CT-scan, if available, will be collected for assessment of skeletal muscle mass index at L3.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Paris, Frankreich, 92042
- Chugai Pharma France
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Patient 18 years of age and older
- Patient with NSCLC
- Patient who has been informed of the study and who has signed a patient information leaflet for France or an informed consent for Belgium
- Patient able to complete a self-assessment questionnaire
Exclusion Criteria:
- Patient unable to consent and/or unable to sign the patient information form in France or an informed consent in Belgium
- Patient with a complete resection of an early stage NSCLC
- History of head and neck cancer
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Querschnitt
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Frequency of Cachexia According to Modified Fearon Criteria
Zeitfenster: Day1
|
Percentage of NSCLC patients with a cachexia according to Fearon criteria modified for the stages of pre-cachexia and refractory cachexia in order to classify all the featured cases without ambiguity. A patient was considered to have cachexia if he/she had:
In the 3 cases defined above, patient should not have entered the refractory cachexia stage, which was defined as: ECOG performance score of 3 or 4 and a low survival expectancy as defined by Martin et al. (J Clin Oncol 2015) (BMI <20 kg/m² and weight loss ≥ 6%) or (20 ≤ BMI ≤ 21.9 kg/m² and weight loss ≥ 11%) or (22 kg/m² ≤ BMI and weight loss ≥ 15%). |
Day1
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Frequency of the Different Stages of Cachexia in the General NSCLC Population
Zeitfenster: Day 1
|
Percentage of the different stages of cachexia at inclusion. The different stages of cachexia used the following classification:
|
Day 1
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC.
Zeitfenster: Day 1
|
Percentage of the different stages of cachexia at inclusion according to the NSCLC stage
|
Day 1
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC.
Zeitfenster: Day 1
|
Percentage of the different stages of cachexia according to the NSCLC histology
|
Day 1
|
Frequency of Sarcopenia in the General NSCLC Patients With Cachexia
Zeitfenster: Day 1
|
Percentage of patients with sarcopenia in the general NSCLC patients with cachexia
|
Day 1
|
Frequency of Sarcopenia With no Clinical Significant Weight Loss in the General NSCLC Patients With Pre-cachexia
Zeitfenster: Day 1
|
Percentage of patient with sarcopenia and no clinical significant weight loss (sarcopenia and WL< 2%) in the general NSCLC patients with pre-cachexia:
|
Day 1
|
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC.
Zeitfenster: Day 1
|
Percentage of the different stages of cachexia according to the molecular abnormalities associated with NSCLC:
|
Day 1
|
Frequency of the Different Stages of Cachexia According to the Number of Treatments Received.
Zeitfenster: Day 1
|
NSCLC patients.
84 patients with missing data
|
Day 1
|
Frequency of the Different Stages of Cachexia According to the Types of Treatments Received.
Zeitfenster: Day 1
|
Stage of cachexia at inclusion according to the type of treatments received (surgery, radiotherapy, chemotherapy, targeted therapies).
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State
Zeitfenster: Day 1
|
• Nutritional state according to the different stages of cachexia The variables used will be: serum albumin levels, serum pre-albumin levels, BMI and weight.
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose
Zeitfenster: Day 1
|
Blood glucose abnormalities according to the different stages of cachexia at inclusion
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale
Zeitfenster: Day 1
|
Dietary Intake Visual Analog Scale (Dietary intake VAS): The question "Could you indicate the amount you currently eat, placing a vertical mark on the line between "nothing at all" and "as usual"?
".
Depending on the location of the patient mark on the scale, a score of between 0 ("nothing at all") and 10 ("as usual") will be allocated.
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT
Zeitfenster: Day 1
|
Score of the 12-question AC/S module (Anorexia-Cachexia module) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire assessing anorexia and cachexia: the AC/S module of the FAACT questionnaire consists of 12 questions to assess over the last 7 days quality of life, related to anorexia or cachexia.
The score ranges between 0 and 48, the higher the score, the higher the quality of life.
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio
Zeitfenster: Day 1
|
neutrophil/lymphocyte ratio
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP
Zeitfenster: Day 1
|
CRP level
|
Day 1
|
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen
Zeitfenster: Day 1
|
fibrinogen level
|
Day 1
|
Description of the Quality of Life Associated With the Different Stages of Cachexia.
Zeitfenster: Day 1
|
Quality of life has been analysed using scores from the functional scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 items (EORTC QLQ-C30 questionnaire): score ranging from 0 (malfunction) to 100 (healthy level of functioning) for the following parameters : physical, role, cognitive, emotional and social scales
|
Day 1
|
Description of the Level of Physical Activity Associated With the Different Stages of Cachexia.
Zeitfenster: Day 1
|
Three levels of physical activity are defined:
Corresponds to one of the following 2 criteria:
|
Day 1
|
Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms
Zeitfenster: Day 1
|
Pharmacological treatment of cachexia or associated symptoms: Yes / No
|
Day 1
|
Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms
Zeitfenster: Day 1
|
Non-pharmacological treatment of cachexia or associated symptoms: Y/N
|
Day 1
|
Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments
Zeitfenster: Day 1
|
Treatments with systemic corticosteroids, anti-inflammatory drugs, Omega 3 fatty acids: Yes/No
|
Day 1
|
Number of Participants With Diabetes Treatments
Zeitfenster: Day 1
|
Diabetes treatments : Yes/No
|
Day 1
|
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia
Zeitfenster: Day 1
|
|
Day 1
|
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia
Zeitfenster: Day 1
|
|
Day 1
|
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition
Zeitfenster: Day 1
|
|
Day 1
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Luz Bobadilla, MD, Chugai Pharma France
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Stoffwechselerkrankungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Ernährungsstörungen
- Körpergewicht
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Änderungen des Körpergewichts
- Abmagerung
- Gewichtsverlust
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Wasting-Syndrom
- Kachexie
Andere Studien-ID-Nummern
- CPF-ANA-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .